This video is featured in the 2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "PALOMA-2 Study - Subcutaneous Amivantamab & Lazertinib as 1L Treatment in Patients With EGFRm Advanced NSCLC"

110 views
June 11, 2024

Chapters

PALOMA-2 Study & Drug Overview

00:00

Efficacy & Safety in EGFRm NSCLC

01:22

Treatment Results & PK Consistency

06:11

0 Comments
Login to view comments. Click here to Login